A Trial Evaluating Escalating Doses and the Safety of Intracystic Injection of NanoPac in Subjects With Mucinous Cystic Pancreatic Neoplasms
Phase of Trial: Phase II
Latest Information Update: 23 Aug 2018
At a glance
- Drugs Paclitaxel (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Nanology
- 15 Aug 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 15 Aug 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Dec 2019.
- 07 Nov 2017 According to a NanOlogy media release, the first patient has been enrolled in this trial.